To develop and validate a prognostic model integrating pretreatment MRI features and clinical characteristics for hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC) combined targeted immunotherapy (TII). A weighted scoring system was developed to improve the model’s clinical utility.

Read the full article on ejradiology.com